Skip to Content

Farydak Approval History

FDA Approved: Yes (First approved February 23, 2015)
Brand name: Farydak
Generic name: panobinostat
Dosage form: Capsules
Company: Novartis Pharmaceuticals Corporation
Treatment for: Multiple Myeloma

Farydak (panobinostat) is a histone deacetylase inhibitor for the combination treatment of multiple myeloma.

Development History and FDA Approval Process for Farydak

DateArticle
Feb 23, 2015Approval FDA Approves Farydak (panobinostat) for Multiple Myeloma
Nov  6, 2014Novartis Announces Outcome of FDA Advisory Committee Meeting for LBH589 (Panobinostat)

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide